Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female adult subjects aged ≥ 18 to ≤ 55 years~* Females must be either postmenopausal or sterile~* Body weight between ≥ 50 and ≤ 110 kg and body mass index between ≥ 18.0 kg/m2 and ≤ 30 kg/m2~Exclusion Criteria:~* History or current evidence of a clinically significant medical condition, disorder, or disease, including but not limited to any of the following: hepatic (hepatitis, cirrhosis, or history of liver disease, drug reaction, or aminotransaminase elevations, if known); biliary; renal; cardiac; bronchopulmonary; vascular; hematologic; gastrointestinal; allergy; endocrine / metabolic (diabetes, thyroid disorders, adrenal disease); neurologic (including history of migraine); psychiatric; immunologic; dermatologic; oncologic (subjects with resected cervical or skin cancer \[except melanoma\] who have had no evidence of disease in the last 5 years are eligible), that precludes designation of healthy subjects as judged by the Investigator~* History or evidence of congenital or acquired immunosuppressive condition(s), including positive serology for human immunodeficiency virus infection or taking immunosuppressive agents.~* Evidence of active or latent tuberculosis~* Hospitalization within 3 months before IP administration or planned hospitalization at any time during the study.~* History of any drug allergy, hypersensitivity (excluding hay fever) or intolerance to latex or any drug product~* A positive test result for drugs of abuse.~* Smokers within 3 months before Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CSL730 (dose 1 with premedication) (Type: EXPERIMENTAL): administered as a single dose by subcutaneous (SC) injection or by SC infusion
- CSL730 (dose 2 with premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 3 with premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 1 without premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 2 without premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 3 without premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 4 without premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 5 without premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 6 without premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- CSL730 (dose 7 without premedication) (Type: EXPERIMENTAL): administered as a single dose by SC injection or by SC infusion
- Placebo (Type: PLACEBO_COMPARATOR): A solution matching the excipient profile of CSL730 without the active substance administered as a single dose by SC injection or by SC infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy